Raptis S, Mitrakou A, Hadjidakis D, Diamantopoulos E, Anastasiou C, Fountas A, Müller R
Second Department of Internal Medicine, Athens University, Greece.
Acta Diabetol Lat. 1987 Jul-Sep;24(3):181-92. doi: 10.1007/BF02732036.
Based on the known action of xanthine derivatives on the insulin secretion, the effect of pentoxifylline on carbohydrate homeostasis of type I (IDDM) and type II (NIDDM) diabetics was investigated. Pentoxifylline is known to exert a favorable influence on hemorheological disturbances in such patients. Twenty-four hour blood glucose pattern and insulin requirements were evaluated in type I and type II diabetics by the use of the artificial pancreas before and after a 14-day treatment with pentoxifylline 400 mg p.o. (Trental 400) t.i.d. During the stabilization period before treatment with pentoxifylline, NIDDM patients required 10.1 +/- 3.8 U of insulin and the IDDM 35 +/- 13.7 U. After 2 weeks on pentoxifylline, NIDDM required only 6.3 +/- 2.8 U (p less than 0.05) and IDDM 28.5 +/- 9.7 U (n.s.). Average blood glucose during the 24h decreased by 15.8 +/- 3.5% in NIDDM and by 10.3 +/- 2.5% in IDDM. Moreover, a significant smoothing of glucose fluctuations during the 24h was noted in both groups. It is concluded that pentoxifylline administered concurrently to any antidiabetic type of treatment leads to better blood glucose control as well as to prevention or delay of vascular complications.
基于黄嘌呤衍生物对胰岛素分泌的已知作用，研究了己酮可可碱对I型（胰岛素依赖型糖尿病，IDDM）和II型（非胰岛素依赖型糖尿病，NIDDM）糖尿病患者碳水化合物稳态的影响。已知己酮可可碱对此类患者的血液流变学紊乱有有利影响。通过使用人工胰腺，在口服400mg己酮可可碱（曲克芦丁400）每日三次进行14天治疗前后，对I型和II型糖尿病患者的24小时血糖模式和胰岛素需求进行了评估。在使用己酮可可碱治疗前的稳定期，NIDDM患者需要10.1±3.8单位胰岛素，IDDM患者需要35±13.7单位胰岛素。使用己酮可可碱2周后，NIDDM患者仅需要6.3±2.8单位（p<0.05），IDDM患者需要28.5±9.7单位（无显著差异）。NIDDM患者24小时内的平均血糖下降了15.8±3.5%，IDDM患者下降了10.3±2.5%。此外，两组患者24小时内血糖波动均显著趋于平稳。得出的结论是，在任何抗糖尿病治疗的同时给予己酮可可碱可导致更好的血糖控制以及预防或延缓血管并发症。
